The p53-inducible E3 ubiquitin ligase p53RFP induces p53-dependent apoptosis  by Huang, Jun et al.
FEBS Letters 580 (2006) 940–947The p53-inducible E3 ubiquitin ligase p53RFP induces
p53-dependent apoptosis
Jun Huanga, Liang-Guo Xub, Ting Liua, Zhonghe Zhaia, Hong-Bing Shuc,*
a Department of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871, China
b National Jewish Medical and Research Center, C080206, USA
c College of Life Sciences, Wuhan University, Wuhan 430072, China
Received 26 July 2005; revised 20 September 2005; accepted 20 September 2005
Available online 18 January 2006
Edited by Varda RotterAbstract Recently, it has been shown that really interesting
new gene (RING)–in between ring ﬁnger (IBR)–RING do-
main-containing proteins, such as Parkin and Parc, are E3 ubiq-
uitin ligases and are involved in regulation of apoptosis. In this
report, we show that p53-inducible RING-ﬁnger protein
(p53RFP), a p53-inducible E3 ubiquitin ligase, induces p53-
dependent but caspase-independent apoptosis. p53RFP contains
an N-terminal RING–IBR–RING domain and an uncharacter-
ized, evolutionally highly conserved C-terminal domain.
p53RFP interacts with E2 ubiquitin-conjugating enzymes
UbcH7 and UbcH8 but not with UbcH5, and this interaction
is mediated through the RING–IBR–RING domain of
p53RFP. Interestingly, the conserved C-terminal domain of
p53RFP is required and suﬃcient for p53RFP-mediated apopto-
sis, suggesting p53RFP-mediated apoptosis does not require its
E3 ubiquitin ligase activity. Together with a recent report show-
ing that p53RFP is involved in ubiquitination and degradation of
p21, a p53 downstream protein promoting growth arrest and
antagonizing apoptosis, our ﬁndings suggest that p53RFP is in-
volved in switching a cell from p53-mediated growth arrest to
apoptosis.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: p53RFP; E3 ubiquitin ligase; p53; Apoptosis;
Growth arrest; Caspase1. Introduction
Apoptosis is an essential process for normal development of
multi-cellular organisms and de-regulation of apoptosis leads
to various diseases, such as cancer and autoimmune diseases
[1–4]. Apoptosis is mediated through two major routes, the
death receptor- and mitochondria-mediated pathways. Each
of which involves the activation of speciﬁc initiator caspases
such as caspase 8 and caspase 9, and downstream caspases
such as caspase 3 [1–4]. Although caspases are critically
involved in the classic apoptotic pathways, numerous studiesAbbreviations: RING, really interesting new gene; p53RFP, p53-
inducible RING-ﬁnger protein; IBR, in between ring ﬁnger; IAP, in-
hibitor of apoptosis
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doi:10.1016/j.febslet.2005.09.105have demonstrated that apoptosis induced by some stimuli is
not inhibited by pan-caspase inhibitors [5–12]. Moreover, gene
knock-out studies suggest that deﬁciency of certain caspases
has no eﬀects on apoptosis triggered by divergent stimuli
[13–17].
Various studies have indicated that the ubiquitin/protea-
some pathway is critically involved in regulation of apoptosis
[18–20]. Ubiquitination is one of the most prevalent and mul-
tifunctional translational modiﬁcation, which involves three
enzymes, including E1 ubiquitin-activating enzyme, E2 ubiqui-
tin-conjugating enzyme, and E3 ubiquitin ligase [21,22]. In the
ubiquitin/proteasome pathway, a substrate is marked for deg-
radation by covalent linkage to ubiquitin. This process in-
volves a highly speciﬁc enzyme cascade in which ubiquitin is
ﬁrst activated by an E1 ubiquitin-activating enzyme and then
transferred to an E2 ubiquitin-conjugating enzyme and ﬁnally
ligated to a substrate by an E3 ubiquitin protein ligase [21,22].
Proteins modiﬁed by ubiquitin are typically recognized and
degraded by the proteasome. However, although targeting
proteins for destruction by the proteasome is the best-charac-
terized task of ubiquitin, recent studies have demonstrated that
ubiquitination also has proteolysis-independent functions,
such as in ubiquitin-dependent endocytosis, transcriptional
control and DNA repair [23,24].
Several E3 ubiquitin ligases have been implicated in regula-
tion of apoptosis-related substrates. One of the well known
apoptosis-related substrates is the cellular protein p53. p53 is
a tumor suppressor mutated in more than half of spontaneous
human cancers [25–27]. p53 protein is normally expressed at
very low level in cells. Under stress conditions, such as DNA
damage, aberrant growth signals and treatment of chemother-
apeutics, p53 protein level is dramatically upregulated [25–27].
Once upregulated, p53, which is also a transcription factor,
can activate a various of downstream genes [25–27]. Most of
the p53 downstream genes are involved in either inducing
apoptosis (such as Bax, Fas, DR5, NOXA, and PUMA) or
causing cell growth arrest and senescence (such as p21 and
GADD45) [25–27].
The normally low level of p53 protein is regulated by a really
interesting new gene (RING)-containing E3 ubiquitin ligase,
called MDM2 [28,29]. Normally, MDM2 binds to and ubiqui-
tinates p53 in the nucleus. This modiﬁcation facilitates the ex-
port of p53 to the cytoplasm and subsequent degradation of
p53 by the proteasome. Under stress conditions, p53 protein
is dramatically upregulated because auto-ubiquitination of
MDM2 is favored and p53 is also stabled by stress-inducedblished by Elsevier B.V. All rights reserved.
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additional E3 ubiquitin ligase, Parc, has been shown to be
involved in regulation of p53-dependent apoptosis [30,31].
Parc contains a RING–in between ring ﬁnger (IBR)–RING
domain found in proteins that control ubiquitin ligase activi-
ties [30,31]. Interestingly, although Parc is an E3 ubiquitin li-
gase and directly binds to p53, it does not cause p53
ubiquitination and degradation. Instead, Parc functions as a
cytoplasmic anchor to retain p53 in the cytoplasm and there-
fore inhibits p53-induced transcription and apoptosis [30,31].
Inhibitors of apoptosis (IAPs) are other examples of E3
ubiquitin ligases that are involved in regulation of apoptosis
[18–20,32]. The IAP family members are characterized by the
presence of up to three tandem repeats of the baculovirus
inhibitor of apoptosis protein repeat (BIR) motif. Most IAP
family members also contain RING ﬁnger domain and have
E3 ubiquitin ligase activity [33–35]. It has been shown that
IAPs inhibit apoptosis through at least two mechanisms. First,
IAPs physically interact with caspases and inhibit caspase acti-
vation [36–38]. Second, IAPs auto-ubiquitinate and ubiquiti-
nate caspases, thus cause degradation of both IAPs and
caspases [33–35].
In this study, we identiﬁed a RING–IBR–RING domain-
containing protein, p53-inducible RING-ﬁnger protein
(p53RFP), which was also recently identiﬁed as a p53-inducible
E3 ubiquitin ligase involved in p21 ubiquitination and degrada-
tion [39]. Our ﬁndings suggest that p53RFP induces p53-depen-
dent and caspase-independent apoptosis and is involved in
switching a cell from p53-mediated growth arrest to apoptosis.2. Materials and methods
2.1. Reagents and cells
Mouse monoclonal antibody against the FLAG (Sigma, St. Louis,
MO) and HA (Covance, Berkely, CA) epitopes, the human embryonic
kidney 293 cells and RD cells (American Tissue Culture Collection,
Manassas, VA) were purchased from the indicated manufacturers.
293 and RD cells were cultured in DMEM medium containing 10%
fetal bovine serum.
2.2. Constructs
The expression plasmid for p53 dominant negative mutant (Dr. Bert
Vogelstein, John Hopkins University), expression plasmids for FLAG-
tagged UbcH5C, UbcH7 and UbcH8 (Dr. Keiji Tanaka and Toshiaki
Suzuki, The Tokyo Metropolitan Institute of Medical Science) were
provided by the indicated investigators. Mammalian expression vec-
tors for HA- or FLAG-tagged p53RFP and its mutants were con-
structed by PCR ampliﬁcation of the corresponding cDNA
fragments and subsequently cloning into a CMV promoter-based vec-
tor containing a N-terminal HA or FLAG tag.
2.3. Northern blot analysis
Human multiple tissue RNA blots were purchased from Clontech
(Palo Alto, CA). The blots were hybridized in the rapid hybridization
buﬀer (Clontech, Palo Alto, CA) under high-stringency condition
with 32P-labeled p53RFP cDNA probe corresponding to the coding
region.
2.4. Transfection and reporter gene assays
Transfection of 293 cells was performed with standard calcium
phosphate precipitation method [46]. 293 cells (1 · 105) were seeded
on 12-well (25 mm) dishes and were transfected the following day.
Within the same experiment, each transfection was performed in trip-
licate, and where necessary, empty control plasmid was added to en-
sure that each transfection to receive the same amount of totalDNA. To normalize for transfection eﬃciency, 0.25 lg of pRL-SV40
Renilla luciferase plasmid was added to each transfection. Dual spe-
ciﬁc luciferase reporter assays were performed using a luciferase assay
kit (Promega, Madison, WI) by following the manufacturer’s proto-
col. Fireﬂy luciferase activities were normalized on the basis of Renilla
luciferase activities.2.5. Co-immunoprecipitation and Western blot analysis
Transfected 293 cells from each 100-mm dish were lysed in 1 ml of
lysis buﬀer (20 mM Tris, pH 7.5, 150 mM NaCI, 1% Triton, 1 mM
EDTA, 10 lg/ml aprotinin, 10 lg/ml leupeptin, 1 mM phenylmethyl-
sulfonyl ﬂuoride). For each immunoprecipitation, 0.4 ml aliquot of ly-
sate was incubated with 0.5 lg of the indicated monoclonal antibody
or control mouse IgG and 25 ll of a 1:1 slurry of Gamma Bind A
Plus-sepharose (Amersham Pharmacia, Piscataway, NJ) for at least
2 h. The sepharose beads were washed three times with 1 ml of lysis
buﬀer containing 500 mM NaCl. The precipitates were fractionated
on SDS–PAGE, and subsequent Western blot analysis was performed
as described [11].2.6. Cell death assays
b-Galactosidase co-transfection assays for determination of cell
death were performed as previously described [41,42]. Brieﬂy, cells
(1 · 105) were seeded on 12-well dishes and transfected the following
day by calcium phosphate precipitation or liposomes with 0.1 lg of
pCMV-b-galactosidase plasmid and the indicated plasmids. Within
the same experiment, each transfection was performed in triplicate,
and where necessary, empty control plasmid was added to ensure each
transfection receives the same amount of DNA. Approximately 36 h
after transfection, cells were stained with X-gal as previously described
[41,42]. The numbers of survived blue cells from ﬁve representative
viewing ﬁelds were determined microscopically. Data shown are aver-
ages and standard deviations of one representative experiments.2.7. DNA fragmentation assays
Transfected 293 cells (1 · 106) were lysed in 200 ll PBS buﬀer con-
taining 0.2 mg/ml of proteinase K, followed by addition of 200 ll PBS
buﬀer containing 2% of NP-40. After mixing at 4 C for 30 min, the
sample was centrifuged and DNA in the supernatant was precipitated
with ethanol. The precipitated DNA was dissolved in 50 ll of H2O
containing 0.2 mg/ml RNase and incubated at 50 C for 2 h. The
DNA sample was then fractionated in a 2% agarose gel.3. Results
3.1. Identiﬁcation and expression of p53 RFP
Previous reports suggest that RING–IBR–RING domain-
containing proteins have E3 ubiquitin ligase activities and
these proteins are usually involved in regulation of apoptosis
[30,31]. Since an E3 ubiquitin ligase recognizes a limited num-
ber of substrates, we reasoned that additional RING–IBR–
RING domain-containing E3 ubiquitin ligases exist. We
searched the GenBanke EST databases and identiﬁed more
than 10 human EST clones that encode a novel RING–IBR–
RING domain-containing protein. This gene, which is referred
as p53RFP, was also reported during the course of this study
[39]. It was demonstrated that p53RFP is a p53-inducible E3
ubiquitin ligase and overexpression of p53RFP causes p21
ubiquitination and degradation [39]. To avoid confusion, we
will refer the protein we identiﬁed also as p53RFP and describe
additional characterization on p53RFP below.
The full-length p53RFP contains 303 amino acids. Blast
searches of the GenBank databases indicated that p53RFP is
mostly homologous with ubiquitin-conjugating enzyme 7
interacting protein 4 (UIP4) [40] (Fig. 1A). p53RFP contains
a RING–IBR–RING domain at its N-terminus and an
Fig. 1. Sequence analysis and expression of human p53RFP. (A) Alignment of the amino acid sequences of human p53RFP and ubiquitin-
conjugating enzyme 7 interacting protein 4 (UIP4). The RING1, IBR, RING2 and C-terminal domain (CTR) are indicated. (B) Alignment of amino
acid sequences of human p53RFP with its putative orthologs in mouse, Drosophila (Dros.) and Anopheles gambiae (Anoph.). (C) Northern blot
analysis of human p53RFP mRNA expression.
942 J. Huang et al. / FEBS Letters 580 (2006) 940–947uncharacterized C-terminal domain (Fig. 1A). The orthologs
of human p53RFP can be found in various species, including
mouse, Drosophila and Anopheles gambiae. Interestingly,
the C-terminal domain of p53RFP is mostly conserved among
the various species (Fig. 1B).To determine the tissue distribution of human p53RFP
expression, we performed Northern blot analysis. The data
suggest that human p53 RFP mRNA is expressed as a single
4.8 kb transcript in most examined tissues, including heart,
placenta, lung, liver, skeletal muscle, kidney, pancreas, pros-
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leukocyte (Fig. 1C). p53RFP mRNA is barely detectable in
brain, spleen and thymus (Fig. 1C).
3.2. UbcH7 and UbcH8, but not UbcH5C, are E2 partners of
p53RFP
Recently, it has been shown that p53RFP is an E3 ubiquitin
ligase [39]. However, the E2 ubiquitin-conjugating enzyme part-
ners for p53RFP are unknown. Since p53RFP is mostly homol-
ogous with UIP4, an E3 ubiquitin ligase that is associated with
the E2 enzyme UbcH7 [40], we determined whether p53RFP
also binds to UbcH7. We co-transfected 293 cells with expres-
sion plasmids for HA-tagged p53RFP and FLAG-tagged
UbcH7, and performed co-immunoprecipitation experiments.
The results indicated that p53RFP interacted with UbcH7
(Fig. 2A). In the same experiments, p53RFP also interacted
with UbcH8 but not UbcH5 (Fig. 2A). These results suggest
that p53RFP speciﬁcally interacts with UbcH7 and UbcH8.
To determine which domain is responsible for p53RFP’s
association with UbcH7 and UbcH8, we constructed twoFig. 2. p53RFP and its RING–IBR–RING domain interact with UbcH7 a
UbcH8 but not UbcH5C. 293 cells (1 · 106) were transfected with 10 lg of a
expression plasmid for FLAG-tagged UbcH7, UbcH8, or UbcH5C. Cell lysat
mouse IgG (C). The immunoprecipitates were analyzed by Western blot
transfected proteins were detected by Western blot analysis anti-HA antibo
RING–IBR–RING domain of p53RFP is required for interaction with Ubc
expression plasmid for HA-tagged p53RFP-(1–222) or p53RFP-(223–303) tog
UbcH8. Cell lysates were immunoprecipitated with anti-HA antibody (aHA)
Western blot with anti-FLAG antibody (upper panel). The expression levels
HA and anti-FLAG antibody (low panel).p53RFP mutants, p53RFP-(1–222) and p53RFP-(223–303),
which contain the N-terminal RING–IBR–RING domain
and the C-terminal domain, respectively. Transient transfec-
tion and co-immunoprecipitation experiments indicated that
p53RFP-(1–222), but not p53RFP-(223–303), interacted with
UbcH7 and UbcH8 (Fig. 2B). These data suggest that the
RING–IBR–RING domain is required and suﬃcient for
p53RFP’s interaction with its E2 partners.
3.3. Induction of apoptosis by p53RFP
To explore the functions of p53RFP, we attempted to estab-
lish stable cell lines that overexpress p53RFP. We transfected
293 cells with an expression plasmid for p53RFP and neomy-
cin, or with a control expression plasmid for neomycin alone.
The transfected cells were selected with G418 for two weeks.
We found that at least ten times less G418 resistant clones were
obtained from p53RFP– than control-transfected cells. More-
over, Western blot analysis indicated that the few G418-
resistant clones obtained from p53RFP transfection did not
express detectable ectopic p53RFP (data not shown). Thesend UbcH8 but not UbcH5C. (A) p53RFP interacts with UbcH7 and
n expression plasmid for HA-tagged p53RFP together with 10 lg of an
es were immunoprecipitated with anti-FLAG antibody (aF) or control
with anti-HA antibody (upper panel). The expression levels of the
dy (middle panel) or with anti-FLAG antibody (low panel). (B) The
H7 and UbcH8. 293 cells (1 · 106) were transfected with 10 lg of an
ether with 10 lg of an expression plasmid for FLAG-tagged UbcH7 or
or control mouse IgG (C). The immunoprecipitates were analyzed by
of the transfected proteins were detected by Western blot analysis anti-
944 J. Huang et al. / FEBS Letters 580 (2006) 940–947experiments suggest that overexpression of p53RFP is lethal to
293 cells.
To directly test whether p53RFP induces cell death, we per-
formed b-galactosidase co-transfection assays in human embry-
onic kidney 293 and rhabdomyosarcoma RD cells [41,42].
These experiments indicated that overexpression of p53RFP in-
duced cell death in 293 and RD cells in a dose-dependent man-
ner (Fig. 3). p53RFP-induced cell death occurred 30 h after
transfection, while death receptors or caspase-8-induced cell
death occurred 14 h after transfection (data not shown). To
determine whether p53RFP induces apoptosis or necrosis, we
examined whether p53RFP induces DNA fragmentation, which
is a hallmark of apoptosis. The results indicated that transient
transfection of p53RFP caused DNA fragmentation in 293 cells
(Fig. 3D). These data suggest that overexpression of p53RFP
induces apoptosis.
3.4. Domain mapping of p53RFP-induced apoptosis
To determine which domain is required for p53RFP-induced
apoptosis, we made N- and C-terminal deletion mutants and
determined their abilities to induce apoptosis. These experi-
ments indicated that the C-terminal fragment (aa223–303)
was suﬃcient to induce apoptosis, whereas the N-terminal
fragments (aa1–222) did not induce apoptosis (Fig. 3D andFig. 3. p53RFP induces apoptosis in 293 and RD cells. (A,B) p53RFP ind
(1 · 105) were transfected with 0.1 lg of CMV-b-gal vector and the indicate
transfection, cells were stained with X-gal, and survived blue cells were counte
empty vector or p53RFP expression plasmid. Condensed and round-up cel
terminal domain causes DNA fragmentation. 293 cells (1 · 106) were transf
after transfection, DNA was isolated from the transfected cells and analyzed
and its mutants. 293 cells (1 · 105) were transfected with 2 lg of expressio
transfection, cell death assays were performed as described in A and B.E). These data suggest that the evolutionarily highly conserved
C-terminal domain, but not the N-terminal RING–IBR–
RING domain, is responsible for p53RFP-induced apoptosis.
3.5. p53RFP-induced apoptosis is dependent on p53 but not
caspase activity
Because p53RFP can induce apoptosis, we examined
whether p53RFP-induced apoptosis is caspase-dependent.
We co-transfected 293 cells with expression plasmids for
p53RFP and crmA, a speciﬁc caspase inhibitor, and performed
cell death assays. The results indicated that crmA could not in-
hibit p53RFP-induced apoptosis. In the same experiments,
crmA inhibited apoptosis induced by RIP, a TNF receptor
1-interacting death domain-containing cytoplasmic protein
(Fig. 4). In addition, a pan-caspase inhibitor, z-VAD-fmk, also
did not inhibit p53RFP-, but inhibited RIP-induced apoptosis
(Fig. 4). These data suggest that p53RFP-induced apoptosis is
caspase-independent.
Because p53-RFP is a p53-inducible RING ﬁnger protein,
we tested whether p53RFP-induced apoptosis is p53-depen-
dent. We co-transfected 293 cells with expression plasmids
for p53RFP and a p53 dominant negative mutant. As shown
in Fig. 4A and B, the p53 dominant negative mutant could
completely block p53RFP-induced apoptosis. Moreover, over-uces cell death in a dose-dependent manner. 293 (A) or RD (B) cells
d amounts of an expression plasmid for p53RFP. Thirty-six hours after
d. (C) The X-gal staining images of 293 cells transfected with 2 lg of an
ls in panel b are dead cells. (D) Overexpression of p53RFP or its C-
ected with 10 lg of the indicated expression plasmids. Thirty-six hours
by 2% agarose gel. (E) Quantitation of apoptosis induced by p53RFP
n plasmids for the indicated p53RFP mutants. Thirty-six hours after
Fig. 4. p53RFP-induced apoptosis is p53-dependent but caspase-independent. (A) Eﬀects of crmA, the pan-caspase inhibitor z-VAD-fmk, p53
dominant negative mutant and Bcl-2 on p53RFP and RIP-induced apoptosis. 293 cells (1 · 105) were transfected with 2 lg of each of the indicated
expression plasmids. Immediately after transfection, the cells were left untreated or treated with z-VAD-fmk (2 lM) for 36 h. The cells were then
stained with X-gal, and the survived cells were counted. (B) DNA fragmentation assays were performed for samples in A. (C) p53RFP induces
apoptosis in wild-type but not p53-deﬁcient HCT116 cells. Wild-type and p53-deﬁcient colon cancer HCT116 cells (1 · 105) were transfected with
0.1 lg of CMV-b-gal vector and 0.5 lg of an expression plasmid for p53RFP or an empty control plasmid. Thirty-six hours after transfection, cells
were stained with X-gal, and survived blue cells were counted.
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p53-deﬁcient HCT116 cells (Fig. 4C). In our experiments, Bcl-
2, a prototypic member of the Bcl-2 family, did not inhibit
p53RFP- or RIP-induced apoptosis (Fig. 4A and B). Taken to-
gether, our data suggest that p53RFP induces p53-dependent
but caspase-independent apoptosis.4. Discussion
The RING–IBR–RING domain-containing E3 ubiquitin li-
gases, such as Parkin and Parc, have been implicated in regu-
lation of apoptosis [30,31,43]. In this paper, we report the
characterization of a p53-inducible RING–IBR–RING do-
main-containing E3 ubiquitin ligase, p53RFP. p53RFP is
mostly homologous with UIP4. Our results indicated that
UIP4 had the same properties with p53RFP in all experiments
performed in the present study (data not shown).
Our data suggest that p53RFP is physically associated with
the E2 ubiquitin-conjugating enzymes UbcH7 and UbcH8 but
not UbcH5. Overexpression of p53RFP induces apoptosis, as
characterized by p53RFP-induced DNA fragmentation.
p53RFP-induced apoptosis is not inhibited by caspase inhibi-
tors, but can be completely inhibited by a dominant negative
mutant of p53. In addition, p53RFP induces in wild-type but
not p53-deiﬁcient HCT116 cells. These data suggest that
p53RFP induces a p53-dependent and caspase-independent
apoptotic pathway.
Domain mapping experiments indicated that the C-terminal
domain, but not the N-terminal RING–IBR–RING domain,
is required and suﬃcient for p53RFP-induced apoptosis.
Therefore, the E3 ubiquitin ligase activity of p53RFP is not re-
quired for p53RFP-induced apoptosis. Previously, it has been
shown that the E3 ubiquitin ligase activity is required for prop-
er functions of some E3 ubiquitin ligases. For example, the
RING ﬁnger domains and thus the E3 ubiquitin ligase activi-
ties of IAPs and MDM2 are absolutely required for their inhi-
bition of apoptosis [28,29,33,34]. On another hand, it has been
shown that Parc-mediated retention of p53 in the cytoplasm
and inhibition of p53-induced apoptosis does not require its
RING–IBR–RING domain and E3 ubiquitin ligase activity
[30,31].
The pro-apoptotic C-terminal domain of p53RFP is
evolutionarily much more conserved than the N-terminal
RING–IBR–RING domain. It is possible that this conserved
C-terminal domain of p53RFP harbors an essential cellular
function. There are several possible mechanisms responsible
for p53RFP-induced apoptosis. For example, the C-terminal
domain of p53RFP may bind to either an activator or inhibitor
in the p53-induced apoptotic pathway and this association
causes activation of the activator or inhibition of the inhibitor.
Or, association of p53RFP through its C-terminal domain
with p53 downstream components may cause changes of these
components’ cellular location and therefore their functions.
Interestingly, the C-terminal domain of p53RFP contains a
stretch of hydrophobic amino acids which may represent a
putative transmembrane domain (Fig. 1).
Consistent with the previous report [39], we found that
p53RFP did not directly interact with p53 or aﬀect p53 stabil-
ity (data not shown).
Interestingly, it has been shown that p53RFP can cause p21
ubiquitination and degradation [39]. P21 is an importanteﬀecter for p53-induced cell growth arrest and senescence. Re-
cent studies have further suggested that p21 also acts as an
inhibitor for p53-induced apoptosis [44,45]. Since p53RFP
can cause both p21 degradation and p53-dependent apoptosis,
it is possible that p53RFP is involved in switching a cell from
p53-induced growth arrest to apoptosis.
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